

January 10, 2025
Fuji Pharma Co., Ltd.

Notice of the launch of Nextstellis™ in drugstores by OLIC (Thailand) Limited

Fuji Pharma Co., Ltd. ("Fuji") announced that Fuji's subsidiary, OLIC (Thailand) Limited ("OLIC"), started marketing Nextstellis™ in drugstores in Thailand on January 6, 2025.

Nextstellis™ is the first product of Fuji Pharma Group marketed outside Japan. The product has been marketed in Thailand since April 2023 for the indication of "contraception". Previously, the drug category could only be sold in hospitals requiring a doctor's prescription. Now the Thai FDA has approved drug category change that enabled marketing in both hospitals and drugstores. This means that the product can now be sold in drugstores in Thailand.

Nextstellis™ combines the native and selective estrogen, estetrol (E₄) with drospirenone (DRSP). Estetrol is a new active ingredient of high clinical interest because of its distinctive mechanism of action that selectively acts on estrogen receptors.

The oral contraceptive market in ASEAN countries is estimated at about 28 billion yen, with Thailand accounting for about 50%. Fuji Pharma Group have market authorization in ASEAN countries other than Thailand and has concluded supply agreement with partners in Vietnam and the Philippines. OLIC expands its business from a pure CMO company to a new hybrid company with CMO and pharmaceutical business with its own brand products.

Fuji Pharma Group will continue to create new value to women's healthcare and contribute to society where everyone can enjoy well-being.

Note

The financial forecasts and other projections provided in this release are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks. Actual results may differ significantly from these forecasts for a number of reasons. It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification. Information in this release about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsks@fujipharma.jp